Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$43.03 USD
+0.05 (0.12%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $43.02 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IONS 43.03 +0.05(0.12%)
Will IONS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IONS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IONS
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
IONS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates
Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: Should You Buy?
Other News for IONS
Insider Sell: Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS)
Raymond James Raises Ionis Pharmaceuticals (IONS) Price Target to $64 | IONS Stock News
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
Ionis Pharmaceuticals (IONS) Receives Analyst Upgrade and Price Target Increase | IONS Stock News
IONS Stock Update: HC Wainwright & Co. Raises Price Target to $65.00 | IONS Stock News